Morphle Labs Inc. has raised USD 5 million in a Series A round led by Inflexor Ventures, accelerating its mission to transform cancer diagnostics with deep tech automation. The Bengaluru-based health-tech innovator will use the fresh capital to expand globally, scale manufacturing, and fast-track regulatory approvals for its advanced medical devices.

This investment fuels the growth of two of Morphle’s pioneering products. RoboTome, a robotic microtome, slices biopsy blocks at over twice the speed of a skilled histotechnologist, ensuring precision and consistency. MorphoLens, a high-throughput scanner, digitizes more than 100 slides per hour using sophisticated optics and AI-driven imaging. Together, these technologies automate critical steps in histology, reducing manual strain while improving speed, accuracy, and diagnostic reliability in pathology labs worldwide.

Led by CEO Rohit Hiwale, CTO Ashish Manmode, and COO Sunnel Daniel, Morphle Labs has filed over 80 patents and currently supports leading labs across the US and Europe. With nearly 100 employees in Bengaluru and Boston, the company plans to strengthen hiring across robotics, optical engineering, computer vision, and medical-grade software — further advancing automation that can dramatically improve turnaround times and outcomes for cancer patients globally.